Does the US Patent System's 'Enablement' Requirement Still Work in the Age of AI and Synthetic Biology?

Imagine spending $50 million to develop an artificial intelligence model that discovers a revolutionary synthetic enzyme capable of breaking down ocean plastics. You file for a patent, only to be told that because you cannot explain exactly how the AI's neural network arrived at the molecular structure step-by-step, you have not "enabled" the public to recreate it. Your invention is denied protection, leaving you vulnerable to copycats and destroying your return on investment.[8]

This is not a hypothetical scenario; it is the central crisis currently fracturing the United States patent system. At the heart of patent law is a simple, centuries-old bargain: the government grants an inventor a 20-year monopoly, and in exchange, the inventor must provide a detailed instruction manual so that anyone else in the field can make and use the invention once the patent expires.[1][8]

Legally, this instruction manual is known as the "enablement" requirement, codified in 35 U.S.C. § 112. The United States Patent and Trademark Office (USPTO) mandates that a patent application must teach a "person having ordinary skill in the art" how to practice the full scope of the claimed invention without requiring "undue experimentation."[1]

For decades, the USPTO and the courts have relied on a predictable set of rules, known as the Wands factors, to determine if an inventor has shared enough information. If you invent a new mechanical gear or a basic chemical compound, you draw the schematics or list the ingredients. The system works perfectly for human-scale, linear engineering where cause and effect are easily documented.[1]

But we no longer live in a purely linear world. Artificial intelligence and machine learning models operate as "black boxes." They ingest massive datasets and adjust billions of internal parameters to produce an output—whether that is a line of code or a novel protein sequence. As legal scholars note, explaining the exact internal logic of an advanced neural network is often technically impossible, fundamentally clashing with the traditional demand for step-by-step disclosure.[3]

Synthetic biology compounds this problem exponentially. Biology is famously classified by patent examiners as an "unpredictable art." Unlike software, where a specific input reliably produces a specific output, biological systems are chaotic. A minor tweak to an amino acid sequence can completely change a protein's function, raising profound questions about who owns the rights to the public domain and the biological commons.[7]

The Supreme Court recently addressed this unpredictability in the landmark 2023 case Amgen v. Sanofi. Amgen had patented a broad class of antibodies that lower cholesterol, claiming millions of potential variations based on a shared function. The Court struck the patent down, ruling that Amgen had not enabled the entire broad class because they only provided a few dozen examples, leaving scientists to engage in "painstaking experimentation" to find the rest.[2]

The Amgen ruling fundamentally reshaped how university and biotech patents are evaluated, demanding exhaustive physical examples for biological claims. But when this strict biological standard collides with AI-driven discovery—a rapidly growing field known as TechBio—the legal framework begins to buckle under its own contradictions.[2][5]

We are witnessing the emergence of a regulatory valley of death. Patent law traditionally treats software as a "predictable art," meaning inventors do not need to disclose every line of code to satisfy enablement. Yet, when that software is used to generate biological innovations, the USPTO applies the "unpredictable art" standard, demanding a level of physical, step-by-step biological disclosure that the AI itself bypassed to make the discovery.[5][8]

This tension is evident in ongoing disputes over foundational technologies like CRISPR. The courts analyze enablement differently when determining if a patent is valid under Section 112 versus when evaluating prior art under Section 102. This creates a bizarre legal asymmetry where an AI-generated biological concept might be detailed enough to block someone else from patenting it, but not detailed enough to earn a patent itself.[6]

If the enablement bar is set too high, requiring impossible levels of human-readable disclosure for AI-generated inventions, companies will simply stop filing patents. Instead, they will guard their algorithms and synthetic organisms as trade secrets. This would be a disaster for the scientific community, which relies on the public disclosure of patents to drive cumulative, shared innovation.[8]

Conversely, if the USPTO lowers the enablement bar to accommodate the black-box nature of AI, we risk a different catastrophe. Patent trolls and aggressive corporations could use AI to generate millions of theoretical chemical structures, patenting them all without ever synthesizing a single one in a lab. This would effectively fence off vast territories of scientific research, demanding tolls from actual scientists.[4]

Some intellectual property experts argue that AI might actually be the solution to its own enablement problem. If AI tools become standard equipment for a "person having ordinary skill in the art," then the baseline capability of the public increases. What was considered "undue experimentation" for a human scientist in 2015 might be a trivial, automated task for an AI-assisted scientist today.[4]

Resolving this debate requires more than just judicial tinkering; it demands a fundamental modernization of how we define human knowledge and disclosure. The patent system must find a way to reward the creation of powerful AI discovery engines without granting them ownership over everything those engines might eventually find.[8]

The enablement requirement is not just a legal technicality; it is the mechanism that ensures innovation serves the public good. As artificial intelligence and synthetic biology merge, redefining what it means to "teach" an invention will determine whether the next century of scientific breakthroughs is shared with the world or locked away in corporate servers.[3][7][8]